Cargando…

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and applicability to individual patients. MRD detected by quantitative polymerase chain reaction,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aitken, Marisa J. L., Ravandi, Farhad, Patel, Keyur P., Short, Nicholas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417965/ https://www.ncbi.nlm.nih.gov/pubmed/34479626 http://dx.doi.org/10.1186/s13045-021-01148-5

Ejemplares similares

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Acute Myeloid Leukemia as a Model for Cancer Therapy
por: Ravandi, Farhad
Publicado: (2012)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
por: Marando, Ludovica, et al.
Publicado: (2020)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020)

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
por: Guerra, Veronica A., et al.
Publicado: (2019)

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
por: Hein, Kyaw, et al.
Publicado: (2022)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors
por: Narlı Özdemir, Zehra, et al.
Publicado: (2021)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Prognostic and therapeutic implications of iron-related cell death pathways in acute myeloid leukemia
por: Li, Tongyu, et al.
Publicado: (2023)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

The present and future of measurable residual disease testing in acute myeloid leukemia
por: Blachly, James S., et al.
Publicado: (2022)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
por: Samra, Bachar, et al.
Publicado: (2020)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
por: Jabbour, Elias, et al.
Publicado: (2023)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f1tmcdjcvalsflu0q3t9gprhf6